Defining phenotypes in COPD: an aid to personalized healthcare.
about
Airflow obstruction: is it asthma or is it COPD?Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): structured literature review and physician insightsDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils.Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.Oxidation pathway and exacerbations in COPD: the role of NAC.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Dual bronchodilation and exacerbations of COPD.Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study.An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?The Challenges of Precision Medicine in COPD.Olodaterol + tiotropium bromide for the treatment of COPD.Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.Use of clinical characteristics to predict spirometric classification of obstructive lung disease.
P2860
Q28067052-C8E35A40-286C-4FF0-8039-F7AC69F0E1AAQ28068805-4DFF94AF-195D-4F05-9E9B-A37D05D38E30Q30249747-C076DC57-6FFD-42FE-B7C6-9C3FE625D829Q37378323-41067AC5-342B-47C3-A0FC-A98024C895DDQ37595806-FD7BB80E-7A94-4AA2-9F8D-1F234FE4BC40Q38266325-D26238E3-860F-4E9F-824D-16A3FB0C6F7EQ38284373-B19BC4AF-D5F5-4EA4-9875-63D8D74D6589Q38633304-AAAF2CE6-243C-48BB-B6A3-6684DD1D5C3EQ38740756-FB61C534-1937-45B8-A448-065E5E249BB5Q38783067-41D96B6E-53BA-4479-B7F3-1CA319E88554Q38832398-302963C6-01AE-4B45-8DB0-D7099D2AD24CQ42384700-FEB950D5-C9FB-4565-BF45-449550048F60Q47112547-B88607FB-8EF6-4373-8307-8EB7F7136542Q47728819-8EE17BED-73D9-4695-9368-D622318527C2Q47962475-87CE3A2F-1E0D-47A7-8083-2F21BD22B511Q51545895-D3B7ECE7-7068-4E78-9824-AA7C49E4D853Q51599981-53ACA954-2BE8-41B8-8E1D-F3EB9C01874DQ55277147-38A585DC-2165-4CE7-AB0E-84801441E108
P2860
Defining phenotypes in COPD: an aid to personalized healthcare.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Defining phenotypes in COPD: an aid to personalized healthcare.
@en
type
label
Defining phenotypes in COPD: an aid to personalized healthcare.
@en
prefLabel
Defining phenotypes in COPD: an aid to personalized healthcare.
@en
P2860
P1476
Defining phenotypes in COPD: an aid to personalized healthcare
@en
P2093
Andrea Segreti
Mario Cazzola
P2860
P2888
P304
P356
10.1007/S40291-014-0100-9
P577
2014-08-01T00:00:00Z
P5875
P6179
1035073260